Sex steroids and gender differences in nonmuscle invasive bladder cancer

Current Opinion in Urology

Volumn 24, Issue 5, 2014, Pages 500-505

  Lucca, Ilaria ^a,b   Fajkovic, Harun ^a   Klatte, Tobias ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

androgens; estrogens; female; gender; sex hormones

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; SEX HORMONE; STEROID RECEPTOR;

BLADDER CARCINOGENESIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; HUMAN; MYCOBACTERIUM BOVIS BCG; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; CANCER STAGING; CARCINOMA, TRANSITIONAL CELL; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; MALE; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

CARCINOMA, TRANSITIONAL CELL; DISEASE PROGRESSION; FEMALE; GONADAL STEROID HORMONES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, STEROID; RISK FACTORS; SEX FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84905368108     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000092     Document Type: Review

References (48)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11-30.
2. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176:2414-2422.
3. Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63:234-241.
4. Ng M, Freeman MK, Fleming TD, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. JAMA 2014; 311:183-192.
5. Tracey E, Roder D, Luke C, Bishop J. Bladder cancer survivals in New South Wales, Australia: why do women have poorer survival than men? BJU Int 2009; 104:498-504.
6. Najari BB, Rink M, Li PS, et al. Sex disparities in cancer mortality: the risks of being a man in the United States. J Urol 2013; 189:1470-1474.
7. Fajkovic H, Halpern JA, Cha EK, et al. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 2011; 29:457-463.
8. Palou J, Sylvester RJ, Faba OR, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol 2012; 62:118-125.
9. American Cancer Society. Cancer Facts and Figures. Internet Publication; 2014. www.cancer.org [Accessed 20 May 2014].
10. Ferlay J, Randi G, Bosetti C, et al. Declining mortality from bladder cancer in Europe. BJU Int 2008; 101:11-19.
11. Mir MC, Stephenson AJ, Grubb RL, et al. Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants. Cancer Epidemiol Biomarkers Prev 2013; 22:2241-2249.
12. McGrath M, Michaud DS, De Vivo I. Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol 2006; 163:236-244.
13. Lortet-Tieulent J, Renteria E, Sharp L, et al. Convergence of decreasing male and increasing female incidence rates in major tobacco-related cancers in Europe in 1988-2010. Eur J Cancer 2013. [Epub ahead of print]. doi: 10.1016/j.ejca.2013.10.014.
14. Henning A, Wehrberger M, Madersbacher S, et al. Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer? BJU Int 2013; 112:68-73.
15. Chamie K, Litwin MS, Bassett JC, et al. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer 2013; 119:3219-3227.
16. Thomas F, Noon AP, Rubin N, et al. Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer. Eur Urol 2013; 63:145-154.
17. Kluth LA, Fajkovic H, Xylinas E, et al. Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World J Urol 2013; 31:1029-1036.
18. Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49:466-475.
19. Fernandez-Gomez J, Solsona E, Unda M, et al., Club Urológico Español de Tratamiento Oncológico (CUETO). Prognostic factors in patients with nonmuscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008; 53:992-1001.
20. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol 2009; 182:2195-2203.
21. Boorjian SA, Zhu F, Herr HW. The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU Int 2010; 106:357-361.
22. Chalasani V, Chin JL, Izawa JI. Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J 2009; 31 Suppl 4:S193-S198.
23. Celayir S, Ilçe Z, Dervisoglu S. The sex hormone receptors in the bladder in childhood - I: preliminary report in male subjects. Eur J Pediatr Surg 2002; 12:312-317.
24. Dairiki Shortliffe LM, Ye Y, Behr B, Wang B. Testosterone changes bladder and kidney structure in juvenile male rats. J Urol 2014. [Epub ahead of print]. doi: 10.1016/j.juro.2014.01.012.
25. Zhang Y. Understanding the gender disparity in bladder cancer risk: the impact of sex hormones and liver on bladder susceptibility to carcinogens. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2013; 31:287-304.
26. Bertram JS, Craig AW. Specific induction of bladder cancer in mice by butyl- (4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response. Eur J Cancer 1972; 8:587-594.
27. Mir C, Shariat SF, van der Kwast TH, et al. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multiinstitutional study. BJU Int 2011; 108:24-30.
28. Han B, Cui D, Jing Y, et al. Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch. World J Urol 2014; 32:149-155.
29. Tuygun C, Kankaya D, Imamoglu A, et al. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: a comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol 2011; 29:43-51.
30. Miyamoto H, Yao JL, Chaux A, et al. Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int 2012; 109:1716-1726.
31. Shen SS, Smith CL, Hsieh J-T, et al. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006; 106:2610-2616.
32. Teng J, Wang Z-Y, Jarrard DF, Bjorling DE. Roles of estrogen receptor alpha and beta in modulating urothelial cell proliferation. Endocr Relat Cancer 2008; 15:351-364.
33. Hsu I, Vitkus S, Da J, Yeh S. Role of oestrogen receptors in bladder cancer development. Nat Rev Urol 2013; 10:317-326.
34. Kauffman EC, Robinson BD, Downes M, et al. Estrogen receptor-b expression and pharmacological targeting in bladder cancer. Oncol Rep 2013; 30:131-138.
35. Bolenz C, Lotan Y, Ashfaq R, Shariat SF. Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. Eur Urol 2009; 56:1093-1095.
36. Tincello DG, Taylor AH, Spurling SM, Bell SC. Receptor isoforms that mediate estrogen and progestagen action in the female lower urinary tract. J Urol 2009; 181:1474-1482.
37. Davis-Dao CA, Henderson KD, Sullivan-Halley J, et al. Lower risk in parous women suggests that hormonal factors are important in bladder cancer etiology. Cancer Epidemiol Biomarkers Prev 2011; 20:1156-1170.
38. Weibull CE, Eloranta S, Altman D. Childbearing and the risk of bladder cancer: a nationwide population-based cohort study. Eur Urol 2013; 63:733-738.
39. Daugherty SE, Lacey JV, Pfeiffer RM, et al. Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH-AARP Diet and Health Study. Int J Cancer 2013; 133:462-472.
40. Cantwell MM, Lacey JV, Schairer C, et al. Reproductive factors, exogenous hormone use and bladder cancer risk in a prospective study. Int J Cancer 2006; 119:2398-2401.
41. Li Y, Izumi K, Miyamoto H. The role of the androgen receptor in the development and progression of bladder cancer. Jpn J Clin Oncol 2012; 42:569-577.
42. Shiota M, Takeuchi A, Yokomizo A, et al. Androgen receptor signaling regulates cell growth and vulnerability to doxorubicin in bladder cancer. J Urol 2012; 188:276-286.
43. Williams C, Lin C-Y. Oestrogen receptors in breast cancer: basic mechanisms and clinical implications. Ecancermedical science 2013; 7:370.
44. Miyamoto H, Zheng Y, Izumi K. Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinoma. Curr Cancer Drug Targets 2012; 12:14-22.
45. Wu J-T, Han B-M, Yu S-Q, et al. Androgen receptor is a potential therapeutic target for bladder cancer. Urology 2010; 75:820-827.
46. Zhai Z, Wang Z, Fu S, et al. Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer. Gene Ther 2012; 19:1065-1074.
47. Hsu I, Chuang K-L, Slavin S, et al. Suppression of ERβ signaling via ERβ knockout or antagonist protects against bladder cancer development. Carcinogenesis 2014; 35:651-661.
48. George SK, Tovar-Sepulveda V, Shen SS, et al. Chemoprevention of BBNinduced bladder carcinogenesis by the selective estrogen receptor modulator tamoxifen. Transl Oncol 2013; 6:244-255.